Clinical Trials Browser

Phase 2 × Completed × alectinib × Clear all

NCT02314481 2026-05-04

DARWINII

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

Neoplasm Metastasis

NCT04632992 2025-01-08

MyTACTIC

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03779191 2023-07-06

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Phase 2 Completed

ALK Gene Rearrangement Positive

NCT03155009 2020-02-10

ATALK

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung